Actelion analyst call presages fireworks at AGM?
This article was originally published in Scrip
Board members at Actelion, the Swiss speciality pharma company, got an early taste on 17 February of the reception they might get when they address shareholders at the company's AGM on 5 May. Dominic Dolinetz from Elliott Advisors, a hedge fund that has a 6% stake in the company, took the microphone during the presentation of Actelion's 2010 results to berate the company's management for stifling discussion and undermining shareholder value. The accusations were robustly rebutted by Dr Jean-Paul Clozel, Actelion's CEO.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.